Paolo Tarantino and Stephen V Liu Shared Study on HER3-DXd in NSCLC After Platinum-Based Chemotherapy and Immunotherapy
Paolo Tarantino, 2025 Yvonne’s “Top Voice” Award Winner, Research Fellow at Dana-Farber Cancer Institute, posted on X by Stephen V Liu, Director of Thoracic Oncology and Associate Professor of Medicine at Georgetown University:
“HER3-DXd seems to have similar activity for lung tumors with and without activating gene mutations. Just as it showed activity across metastatic breast cancer subtypes.
To date, no biomarker has been found to reliably predict the activity of HER3-DXd. Similar to most other ADCs.”
Quoting Stephen V Liu‘s post:
“Report JCO on patritumab deruxtecan (HER3 ADC, HER3-DXd) in NSCLC without an EGFR mutation (n=47). RR 28%, DOR 8m, PFS 5.5m, OS 15m. Similar efficacy with or without AGA. G3+ TEAEs in 51% with 13% discontinuation due to TEAE. ILD rate ~10%.
While this compares favorably across trials with cytotoxics like docetaxel, I’m hoping that a wider therapeutic window will be created by use of a biomarker like NMR/QCS that reflects the need for internalization to trigger payload release.”
Title: Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy
Journal: JCO
Authors: Conor E. Steuer, Hidetoshi Hayashi, Wu-Chou Su, Makoto Nishio, Melissa L. Johnson, Dong-Wan Kim, Erminia Massarelli, Enriqueta Felip, Kathryn A. Gold, Haruyasu Murakami, Christina S. Baik, Sang-We Kim, Egbert F. Smit, Masahiro Fujimura, Pang-Dian Fan, Karine Truchon, Xin Su, David W. Sternberg, Pasi A. Jänne
More posts featuring Paolo Tarantino and Stephen V Liu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023